Abstract
To date, animal models have not sufficiently ‘‘filtered’’ targets for new analgesics, increasing the failure rate and cost of drug development. Preclinical assessment of ‘‘pain’’ has historically relied on measures of evoked behavioral responses to sensory stimuli in animals. Such measures can often be observed in decerebrated animals and therefore may not sufficiently capture affective and motivational aspects of pain, potentially diminishing translation from preclinical studies to the clinical setting. Further, evidence indicates that there are important mechanistic differences between evoked behavioral responses of hypersensitivity and ongoing pain, limiting evaluation of mechanisms that could mediate aspects of clinically relevant pain. The mechanisms underlying ongoing pain in preclinical models are currently being explored and may serve to inform decisions towards the transition from drug discovery to drug development for a given target.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 101-120 |
| Number of pages | 20 |
| Journal | Current Topics in Behavioral Neurosciences |
| Volume | 20 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
Keywords
- Affective
- Motivational behaviors
- Ongoing pain
- Translation
ASJC Scopus subject areas
- Behavioral Neuroscience
Cite this
Preclinical assessment of pain : Improving models in discovery research. / King, Tamara; Porreca, Frank.
In: Current Topics in Behavioral Neurosciences, Vol. 20, 2014, p. 101-120.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Preclinical assessment of pain
T2 - Improving models in discovery research
AU - King, Tamara
AU - Porreca, Frank
PY - 2014
Y1 - 2014
N2 - To date, animal models have not sufficiently ‘‘filtered’’ targets for new analgesics, increasing the failure rate and cost of drug development. Preclinical assessment of ‘‘pain’’ has historically relied on measures of evoked behavioral responses to sensory stimuli in animals. Such measures can often be observed in decerebrated animals and therefore may not sufficiently capture affective and motivational aspects of pain, potentially diminishing translation from preclinical studies to the clinical setting. Further, evidence indicates that there are important mechanistic differences between evoked behavioral responses of hypersensitivity and ongoing pain, limiting evaluation of mechanisms that could mediate aspects of clinically relevant pain. The mechanisms underlying ongoing pain in preclinical models are currently being explored and may serve to inform decisions towards the transition from drug discovery to drug development for a given target.
AB - To date, animal models have not sufficiently ‘‘filtered’’ targets for new analgesics, increasing the failure rate and cost of drug development. Preclinical assessment of ‘‘pain’’ has historically relied on measures of evoked behavioral responses to sensory stimuli in animals. Such measures can often be observed in decerebrated animals and therefore may not sufficiently capture affective and motivational aspects of pain, potentially diminishing translation from preclinical studies to the clinical setting. Further, evidence indicates that there are important mechanistic differences between evoked behavioral responses of hypersensitivity and ongoing pain, limiting evaluation of mechanisms that could mediate aspects of clinically relevant pain. The mechanisms underlying ongoing pain in preclinical models are currently being explored and may serve to inform decisions towards the transition from drug discovery to drug development for a given target.
KW - Affective
KW - Motivational behaviors
KW - Ongoing pain
KW - Translation
UR - http://www.scopus.com/inward/record.url?scp=84922015061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922015061&partnerID=8YFLogxK
U2 - 10.1007/7854_2014_330
DO - 10.1007/7854_2014_330
M3 - Article
AN - SCOPUS:84922015061
VL - 20
SP - 101
EP - 120
JO - Current Topics in Behavioral Neurosciences
JF - Current Topics in Behavioral Neurosciences
SN - 1866-3370
ER -